IL7 and glioma: Interestingly, while combination IL-7 ALT + αPD-1 therapy exhibited a limited survival benefit in the CT2AvIII glioma model (Figure 2D), greater efficacy was observed in mice bearing more immunogenic GL261 gliomas (35) (Figure 2F).